Verition Fund Management LLC Mirati Therapeutics, Inc. Transaction History

Verition Fund Management LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$41.99 - $62.38 $6.71 Million - $9.97 Million	-159,880 Reduced 77.43%	46,599 $2.74 Million
Q3 2023 Nov 14, 2023	BUY	$27.8 - $45.35 $5.53 Million - $9.02 Million	198,801 Added 2589.23%	206,479 $8.99 Million
Q2 2023 Aug 14, 2023	SELL	$36.13 - $49.49 $143,725 - $196,871	-3,978 Reduced 34.13%	7,678 $277,000
Q1 2023 May 15, 2023	BUY	$36.54 - $54.26 $224,538 - $333,427	6,145 Added 111.5%	11,656 $433,000
Q4 2022 Feb 14, 2023	SELL	$41.27 - $98.62 $6,685 - $15,976	-162 Reduced 2.86%	5,511 $249,000

Q2 2022 Aug 15, 2022	BUY	$39.16 - $88.71 $222,154 - $503,251	5,673 New	5,673 $381,000
Q1 2022 May 13, 2022	SELL	$75.82 - $150.97 $2.43 Million - $4.84 Million	-32,027 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$132.01 - $190.29 $1.22 Million - $1.76 Million	9,231 Added 40.49%	32,027 $4.7 Million
Q3 2021 Nov 15, 2021	BUY	$132.13 - $177.45 $2.59 Million - $3.48 Million	19,631 Added 620.25%	22,796 $4.03 Million
Q2 2021 Aug 16, 2021	BUY	$144.0 - $179.73 $455,760 - $568,845	3,165 New	3,165 $511,000
Q2 2018 Aug 15, 2018	SELL	$26.05 - $52.4 $238,123 - $478,988	-9,141 Closed	0 $0
Q1 2018 May 16, 2018	BUY	$17.2 - $34.95 $157,225 - $319,477	9,141 New	9,141 $281,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Verition Fund Management LLC, based on Form 13F filings with the SEC.

Stay updated on Verition Fund Management LLC with notifications on news.